---
title: "BriaCell Therapeutics 3Q FY2026: Net loss $(7.16M), EPS $(0.99) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289232454.md"
description: "BriaCell Therapeutics reported a Q3 FY2026 net loss of $7.16M and EPS of $(0.99), widening from the prior year's $6.13M loss. Year-to-date net loss reached $22.58M. Clinically, the Phase 3 Bria-IMT™ trial for metastatic breast cancer is advancing with over 160–230 patients enrolled and five positive DSMB reviews. The company also secured $2M in NCI SBIR funding, expanded its pipeline with cleared INDs, and increased operational spending to support accelerated clinical enrollment."
datetime: "2026-06-09T20:11:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289232454.md)
  - [en](https://longbridge.com/en/news/289232454.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289232454.md)
generator: "portal-rs"
---

# BriaCell Therapeutics 3Q FY2026: Net loss $(7.16M), EPS $(0.99) — 10-Q Summary

BriaCell Therapeutics Corp. reported a net loss of $(7.16M) for the third quarter of fiscal 2026, compared with a net loss of $(6.13M) in the year-ago quarter; diluted loss per share was $(0.99) versus $(16.42) in the prior-year quarter. For the nine months ended April 30, 2026, BriaCell recorded a year-to-date net loss of $(22.58M), up from $(18.22M) a year earlier.

**Financial Highlights**

-   Net loss: $(7.16M) for 3Q FY2026, versus $(6.13M) in the year-ago quarter (wider loss YoY).
-   Diluted earnings per share: $(0.99) for 3Q FY2026, versus $(16.42) in the year-ago quarter.
-   Net loss (YTD): $(22.58M) for the nine months ended Apr 30, 2026, versus $(18.22M) year-ago (increased loss YoY).

**Business Highlights**

-   Clinical progress: The pivotal Phase 3 Bria-IMT™ trial in metastatic breast cancer is advancing, with more than 160–230+ patients enrolled and five positive Data Safety Monitoring Board (DSMB) reviews reported.
-   Efficacy & biomarkers: Phase 2/3 data show benchmark-beating survival outcomes, durable responders, and emerging Th1 biomarker signatures supporting the program.
-   Pipeline expansion: Bria-OTS/OTS+ moved to GMP supplies; IND cleared for Bria-BRES+ and manufacturing for Bria-PROS+ completed.
-   Collaborations & non-dilutive funding: Participation in the MSK Therapeutics Accelerator cohort, a $2M NCI SBIR award, and collaboration with MSK to support IND and clinical work.
-   Operational scale-up: Company increased clinical site additions and CRO, manufacturing and clinical spending to support accelerated enrollment in its trials.

Original SEC Filing: BriaCell Therapeutics Corp. \[ BCTX \] - 10-Q - Jun. 09, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BCTXW.US](https://longbridge.com/en/quote/BCTXW.US.md)
- [BCTX.US](https://longbridge.com/en/quote/BCTX.US.md)
- [BCTXZ.US](https://longbridge.com/en/quote/BCTXZ.US.md)
- [BCTXL.US](https://longbridge.com/en/quote/BCTXL.US.md)

## Related News & Research

- [BriaCell says Bria-MEL+ melanoma vaccine candidate hits genetic engineering milestone](https://longbridge.com/en/news/296780600.md)
- [BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ | BCTX Stock News](https://longbridge.com/en/news/296784224.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**